Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–1 of 1 stories
FDA has approved the first human trial of Life Biosciences' ER-100, a gene therapy aimed at rejuvenating retinal cells in patients with age-related eye diseases. This Phase 1 study will focus on conditions such as open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION).
Get the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.